Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/10/26	US$0.5631	+4.07%	403,020
28/10/26	US$0.5411	+7.90%	203,194
27/10/26	US$0.5015	+11.62%	525,537
26/10/26	US$0.4493	+11.38%	377,887
23/10/26	US$0.4034	+8.79%	435,498

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.5631USD

Average target price

4.000USD

Spread / Average Target

+610.35%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Citius Pharmaceuticals, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Citius Pharmaceuticals, Inc.

Company calendar

Market Closed - Nasdaq 20:00:00 29/10/2026 GMT			5-day change	1st Jan Change
0.5631 ^USD	+4.07%		+51.86%	-27.53%

08-14	Citius Oncology, Inc. Announces Appointment of Jonathan Peri, Ph.D., J.D., as Independent Director, Effective August 10, 2026	CI
08-14	Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI

Market Cap	15.46M 13.85M 12.77M 11.56M 21.62M 1.47B 21.97M 152M 60.8M 770M 58.01M 56.78M 2.44B	P/E 2026 *	-0.28x	P/E 2027 *	-0.39x
Enterprise Value	15.46M 13.85M 12.77M 11.56M 21.62M 1.47B 21.97M 152M 60.8M 770M 58.01M 56.78M 2.44B	EV / Sales 2026 *	1.54x	EV / Sales 2027 *	0.75x
Free-Float	98.2%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	CTXR	Delayed
CBOE	CTXR	Real-time

08-14	Citius Oncology, Inc. Announces Appointment of Jonathan Peri, Ph.D., J.D., as Independent Director, Effective August 10, 2026	CI
08-14	Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
05-15	Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
03-10	Citius Oncology, Inc. Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of Lymphir in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers	CI
02-13	Citius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-11	Citius Oncology expands international distribution of Lymphir™ to European Union through exclusive agreement with Uniphar	RE
12-23	Citius Pharmaceuticals, Inc. reports fiscal year 2025 financial results and provides business update	RE
12-23	Citius Oncology Fiscal 2025 Loss Widens	MT
12-23	Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-22	Citius Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
12-09	Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules	RE
12-04	Citius Oncology expands Lymphir distribution to Turkey and Middle East countries	RE
21/10/25	Citius Pharmaceuticals announces the closing of registered direct offering of $6.0 million priced at-the-market under Nasdaq rules	RE

Citius Pharmaceuticals, Inc. Share Price

Stocks

CTXR

US17322U3068

Biotechnology & Medical Research

Valuation: Citius Pharmaceuticals, Inc.

Chart: Citius Pharmaceuticals, Inc.

Latest news: Citius Pharmaceuticals, Inc.

Analysts' recommendations: Citius Pharmaceuticals, Inc.

Press Releases: Citius Pharmaceuticals, Inc.

News in other languages: Citius Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Citius Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

01/08/23	HC Wainwright Adjusts Citius Pharmaceuticals Price Target to $4 From $6, Maintains Buy Rating	MT
18/01/22	HC Wainwright Adjusts Citius Pharmaceuticals Price Target to $6 From $4, Maintains Buy Rating	MT
30/11/21	Maxim Group Initiates Coverage on Citius Pharmaceuticals With Buy Rating, $4 Price Target	MT

10-12	Citius Pharmaceuticals to Participate in October 2026 Investor Conferences	PR
08-12	Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri	PR
05-26	Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting	PR
05-15	Citius Pharmaceuticals : Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update	PU
05-15	Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update	PR

1 day	+4.07%
1 week	+51.86%
Current month	+6.05%
1 month	+1.55%
3 months	-1.04%
6 months	-5.38%
Current year	-27.53%

1 week	0.39	0.61
1 month	0.37	0.61
Current year	0.37	1.08
1 year	0.37	1.6
3 years	0.37	26.75
5 years	0.37	50.5
10 years	0.37	371.23

Manager	Title	Age	Since
Leonard Mazur CEO	Chief Executive Officer	81	30/04/2022
Jaime Bartushak DFI	Director of Finance/CFO	59	26/11/2017
Myron Czuczman CTO	Chief Tech/Sci/R&D Officer	66	13/07/2020

Director	Title	Age	Since
Leonard Mazur CHM	Chairman	81	29/02/2016
Myron Holubiak BRD	Director/Board Member	79	30/09/2015
Suren Dutia BRD	Director/Board Member	83	30/09/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
08/08/25	Leonard Mazur	Other	Chief Executive Officer	429,756	5.0010%
08/08/25	Myron Holubiak	Other	Founder	107,434	1.2502%
07/11/24	Myron Holubiak	Other	Founder	425,000	0.2352%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CITIUS PHARMACEUTICALS, INC.	+4.07%	+51.86%	-62.71%	-96.95%	14.85M
WUXI APPTEC CO., LTD.	+0.34%	+1.12%	+34.75%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.68%	+12.25%	+82.98%	55.53B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+103.69%	53.03B
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+52.86%	45.99B
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+117.99%	42.45B
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+922.41%	40.45B
CELLTRION, INC.	-0.26%	-2.57%	+12.55%	+45.18%	32.25B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+88.74%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	+0.09%	-1.53%	+23.29%	-10.69%	24.23B
Average	+0.38%	+9.04%	+40.94%	+136.73%	39.26B
Weighted average by Cap.	+0.10%	+3.59%	+49.30%	+160.56%

	2026 *	2027 *
Net sales	10.05M 9M 8.31M 7.52M 14.05M 957M 14.28M 99.09M 39.53M 501M 37.72M 36.92M 1.59B	20.52M 18.38M 16.96M 15.35M 28.7M 1.95B 29.16M 202M 80.71M 1.02B 77.02M 75.38M 3.24B
Net income	-60.7M -54.36M -50.15M -45.39M -84.87M -5.78B -86.24M -598M -239M -3.02B -228M -223M -9.58B	-41.79M -37.43M -34.53M -31.25M -58.43M -3.98B -59.37M -412M -164M -2.08B -157M -153M -6.6B
Net Debt	-	-